Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry
Open Access
- 6 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Research in Cardiology
- Vol. 110 (1), 102-113
- https://doi.org/10.1007/s00392-020-01657-2
Abstract
Background The prospective WEARIT-II-EUROPE registry aimed to assess the value of the wearable cardioverter-defibrillator (WCD) prior to potential ICD implantation in patients with heart failure and reduced ejection fraction considered at risk of sudden arrhythmic death. Methods and results 781 patients (77% men; mean age 59.3 ± 13.4 years) with heart failure and reduced left ventricular ejection fraction (LVEF) were consecutively enrolled. All patients received a WCD. Follow-up time for all patients was 12 months. Mean baseline LVEF was 26.9%. Mean WCD wearing time was 75 ± 47.7 days, mean daily WCD use 20.3 ± 4.6 h. WCD shocks terminated 13 VT/VF events in ten patients (1.3%). Two patients died during WCD prescription of non-arrhythmic cause. Mean LVEF increased from 26.9 to 36.3% at the end of WCD prescription (p < 0.01). After WCD use, ICDs were implanted in only 289 patients (37%). Forty patients (5.1%) died during follow-up. Five patients (1.7%) died with ICDs implanted, 33 patients (7%) had no ICD (no information on ICD in two patients). The majority of patients (75%) with the follow-up of 12 months after WCD prescription died from heart failure (15 patients) and non-cardiac death (15 patients). Only three patients (7%) died suddenly. In seven patients, the cause of death remained unknown. Conclusions Mortality after WCD prescription was mainly driven by heart failure and non-cardiovascular death. In patients with HFrEF and a potential risk of sudden arrhythmic death, WCD protected observation of LVEF progression and appraisal of competing risks of potential non-arrhythmic death may enable improved selection for beneficial ICD implantation. Graphic abstractKeywords
Funding Information
- Zoll CMS (Research Grant)
This publication has 38 references indexed in Scilit:
- Role of the Wearable Defibrillator in Newly Diagnosed Heart FailureCurrent Heart Failure Reports, 2018
- Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator ExplantJACC: Clinical Electrophysiology, 2017
- The wearable cardioverter-defibrillator: current technology and evolving indicationsEP Europace, 2016
- Use of the Wearable Cardioverter Defibrillator in High-Risk Cardiac PatientsCirculation, 2015
- 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac deathEP Europace, 2015
- Evolution of Left Ventricular Ejection Fraction After Acute Myocardial InfarctionCirculation, 2014
- Wearable Cardioverter-Defibrillator Use in Patients Perceived to Be at High Risk Early Post-Myocardial InfarctionJournal of the American College of Cardiology, 2013
- Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillatorEuropean Heart Journal, 2013
- Aggregate National Experience With the Wearable Cardioverter-Defibrillator: Event Rates, Compliance, and SurvivalJournal of the American College of Cardiology, 2010
- Use of a Wearable Defibrillator in Terminating Tachyarrhythmias in Patients at High Risk for Sudden Death:. Results of WEARIT/BIROADPacing and Clinical Electrophysiology, 2004